Skip to main content

Table 2 Factors contributing to Physical Summary Score (PhS) in 60 patients with new-onset polyarticular juvenile idiopathic arthritis

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 UnivariateMixed Model
β (95% CI)/Mean PhS (95% CI)pβ (95% CI)p
Gender (mean) 0.14  
 Female44.5 (40.7 to 48.3)   
 Male39.9 (34.9 to 44.8)   
Time of visit (weeks)a <0.001 <0.001
026.22 (22.04 to 30.39) 35.46 (30.91 to 40.04) 
633.53 (29.43 to 37.63) 38.38 (34.30 to 42.46) 
1238.69 (34.59 to 42.79) 39.95 (36.34 to 43.55) 
2447.98 (43.76 to 52.19) 43.57 (41.63 to 45.86) 
3648.07 (43.81 to 52.32) 44.62 (42.04 to 47.19) 
4849.80 (45.54 to 54.05) 44.29 (41.07 to 47.51) 
5451.66 (47.40 to 55.91) 46.51 (43.66 to 49.35) 
Age at onset-0.01 (-0.97 to 0.95)0.98  
Treatment (mean) b 0.043 0.419
IFX+ MTX46.2 (41.0 to 50.5)0.046c40.19 (36.98 to 43.42) 
Triple45.5 (40.4 to 50.5)0.065d42.70 (39.85 to 45.55) 
MTX38.7 (33.5 to 43.9) 42.65 (39.53 to 45.78) 
JADAS10-1.258 (-1.45 to -1.06)<0.001-0.347(-0.72 to 0.024)0.067
Pain-VAS-0.432 (-0.49 to -0.38)<0.001-0.204 (-0.28 to -0.12)<0.001
Corticosteroid usee-0.473 (-0.64 to -0.30)<0.001-0.004 (-0.019 to 0.10)0.554
Time in remissionf0.204 (0.073 to 0.334)0.0030.172 (0.05 to 0.29)0.005
CHAQ-23.25 (-26.1 to -20.4)<0.001-11.2 (-15.8 to -6.67)<0.001
CHAQ*JADAS  0.087 (-0.29 to 0.47)0.658
  1. For numerical factors, Coefficient beta indicated; for categorical values mean PhS value indicated.
  2. Sidak correction for multiple comparisons used. Factors with p-value <0.05 in univariate analyses were selected for multivariate mixed model. Values shown in Mixed Model column have been adjusted with other variables in the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate, hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, CHAQ child health assessment questionnaire, PhS Physical summary Score. aValues present mean (95% CI) PhS in all patients at each time point bValues present mean (95%CI) PhS at all time points in each treatment group cIFX+MTX vs MTX; dTriple vs MTX; for IFX+MTX vs Triple p=0.84; eAmount of corticosteroids per body weight (intra-articular or oral) before individual study visit, adjusted for 6 weeks’ time (mg/kg); fCumulative time in remission since onset, *interaction term